Quarterly report pursuant to Section 13 or 15(d)

GENERAL (Details Narrative)

v3.22.1
GENERAL (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 11, 2022
Jul. 02, 2021
Apr. 19, 2021
Mar. 31, 2022
Mar. 31, 2021
Mar. 14, 2022
Mar. 10, 2022
Dec. 31, 2021
Dec. 31, 2020
Jul. 28, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Debt Instrument, Face Amount             $ 1,804      
Share Price       $ 0.02            
Retained Earnings (Accumulated Deficit)       $ 98,183       $ 90,595    
Working capital       6,778            
Stockholders' Equity Attributable to Parent       25,161 $ 19,458     $ 24,212 $ 11,011  
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents       28            
Revenues Recognized       $ 2,199 $ 5,031          
Breakthrough Diagnostics Inc [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Percentage of Issued and Outstanding Common Stock                   100.00%
Provista Diagnostic Inc [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Share Price   $ 0.05                
Payments for Repurchase of Common Stock   $ 1,170                
Provista Diagnostic Inc [Member] | Maximum [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Share Price   $ 0.05                
Debt Instrument, Convertible, Conversion Price   $ 0.05                
Provista Diagnostic Inc [Member] | Convertible Note [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Debt Instrument, Face Amount     $ 3,500              
Share purchase agreement [Member] | 3CL Science Ltd [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Equity Method Investment, Ownership Percentage 52.00%                  
Stock Issued During Period, Value, New Issues $ 10,000                  
Share purchase agreement [Member] | NLC Pharma Ltd [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Equity Method Investment, Ownership Percentage 48.00%                  
Share purchase agreement [Member] | Provista Diagnostics Inc [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Stock Issued During Period, Value, New Issues     1,500              
Sale of Stock, Consideration Received on Transaction     7,500              
Deposits     $ 1,250              
Shares Issued, Price Per Share     $ 0.0512              
Cash Deposits     $ 1,250              
Securities Purchase Agreement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Stock Issued During Period, Value, New Issues $ 3,800                  
Line Of Credit Agreement [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Equity Method Investment, Ownership Percentage           10.00%